Vericel (VCEL) Current Assets (2010 - 2026)
Vericel (VCEL) posted Current Assets of $264.7 million for Q2 2026, up 8.47% sequentially from $244.1 million in Q1 2026, and up 29.4% YoY from $204.6 million in Q2 2025.
Analysis
Vericel (VCEL) Current Assets (2010 - 2026) Analysis & Trends
Vericel has reported Current Assets for 17 years, with the latest figure at $264.7 million in Q2 2026.
- Quarterly Current Assets rose 29.4% year-over-year to $264.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $264.7 million (up 29.4% YoY) and the FY2025 annual result came in at $247.4 million, up 16.29% from the prior year.
- Current Assets improved to $264.7 million in Q2 2026 per VCEL's latest filing, from $244.1 million in the prior quarter.
- Over five years, Current Assets peaked at $264.7 million in Q2 2026 and troughed at $151.9 million in Q1 2022.
- A 5-year average of $199.1 million and a median of $194.0 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2026: Current Assets grew 2.31% in 2024, then gained 29.4% in 2026.
- Over 5 years, Current Assets stood at $186.9 million in 2022, then gained by 10.04% to $205.6 million in 2023, then rose by 3.48% to $212.8 million in 2024, then grew by 16.29% to $247.4 million in 2025, then grew by 6.99% to $264.7 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $264.7 million, $244.1 million, and $247.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 264.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 264.73 Mn |
| Mar 31, 2026 | 244.06 Mn |
| Dec 31, 2025 | 247.44 Mn |
| Sep 30, 2025 | 221.97 Mn |
| Jun 30, 2025 | 204.58 Mn |
| Mar 31, 2025 | 197.64 Mn |
| Dec 31, 2024 | 212.78 Mn |
| Sep 30, 2024 | 190.52 Mn |
| Jun 30, 2024 | 197.39 Mn |
| Mar 31, 2024 | 189.72 Mn |
| Dec 31, 2023 | 205.63 Mn |
| Sep 30, 2023 | 186.21 Mn |
| Jun 30, 2023 | 182.87 Mn |
| Mar 31, 2023 | 177.55 Mn |
| Dec 31, 2022 | 186.87 Mn |
| Sep 30, 2022 | 166.38 Mn |
| Jun 30, 2022 | 155.09 Mn |
| Mar 31, 2022 | 151.88 Mn |
| Dec 31, 2021 | 158.46 Mn |
| Sep 30, 2021 | 144.95 Mn |